Literature DB >> 18442906

Novel bis-(arylsulfonamide) hydroxamate-based selective MMP inhibitors.

Rajesh Subramaniam1, Manas K Haldar, Shakila Tobwala, Bratati Ganguly, D K Srivastava, Sanku Mallik.   

Abstract

A series of bis-(arylsulfonamide) hydroxamate inhibitors were synthesized. These compounds exhibit good potency against MMP-7 and MMP-9 depending on the nature, steric bulk, and substitution pattern of the substituents in the benzene ring. In general, the preliminary structure-activity relationships (SAR) suggest that among the DAPA hydroxamates (i) electron-rich benzene rings of the sulfonamides may produce better inhibitors than electron-poor analogs. However, potential H-bond acceptors can reverse the trend depending on the isozyme; (ii) isozyme selectivity between MMP-7 and -9 can be conferred through steric bulk and substitution pattern of the substituents in the benzene ring, and (iii) the MMP-10 inhibition pattern of the compounds paralleled that for MMP-9.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18442906      PMCID: PMC2490768          DOI: 10.1016/j.bmcl.2008.04.035

Source DB:  PubMed          Journal:  Bioorg Med Chem Lett        ISSN: 0960-894X            Impact factor:   2.823


  23 in total

1.  Design and therapeutic application of matrix metalloproteinase inhibitors.

Authors:  M Whittaker; C D Floyd; P Brown; A J Gearing
Journal:  Chem Rev       Date:  1999-09-08       Impact factor: 60.622

Review 2.  Matrix metalloproteinases and their inhibitors in vascular remodeling and vascular disease.

Authors:  Joseph D Raffetto; Raouf A Khalil
Journal:  Biochem Pharmacol       Date:  2007-07-07       Impact factor: 5.858

Review 3.  Matrix metalloproteinases as valid clinical targets.

Authors:  Barbara Fingleton
Journal:  Curr Pharm Des       Date:  2007       Impact factor: 3.116

Review 4.  Matrix metalloproteinase inhibitors as therapy for inflammatory and vascular diseases.

Authors:  Jialiang Hu; Philippe E Van den Steen; Qing-Xiang A Sang; Ghislain Opdenakker
Journal:  Nat Rev Drug Discov       Date:  2007-06       Impact factor: 84.694

Review 5.  Matrix metalloproteinases: useful and deleterious.

Authors:  E Ganea; M Trifan; A C Laslo; G Putina; C Cristescu
Journal:  Biochem Soc Trans       Date:  2007-08       Impact factor: 5.407

Review 6.  Matrix metalloproteinases (MMPs): chemical-biological functions and (Q)SARs.

Authors:  Rajeshwar P Verma; Corwin Hansch
Journal:  Bioorg Med Chem       Date:  2007-01-17       Impact factor: 3.641

Review 7.  The other side of MMPs: protective roles in tumor progression.

Authors:  Michelle D Martin; Lynn M Matrisian
Journal:  Cancer Metastasis Rev       Date:  2007-12       Impact factor: 9.264

Review 8.  Matrix metalloproteinase-9/gelatinase B is a putative therapeutic target of chronic obstructive pulmonary disease and multiple sclerosis.

Authors:  M E Muroski; M D Roycik; R G Newcomer; P E Van den Steen; G Opdenakker; H R Monroe; Z J Sahab; Q-X Sang
Journal:  Curr Pharm Biotechnol       Date:  2008-02       Impact factor: 2.837

Review 9.  Protease inhibitors of the sulfonamide type: anticancer, antiinflammatory, and antiviral agents.

Authors:  Claudiu T Supuran; Angela Casini; Andrea Scozzafava
Journal:  Med Res Rev       Date:  2003-09       Impact factor: 12.944

10.  Matrix metalloproteinase 7 mediates mammary epithelial cell tumorigenesis through the ErbB4 receptor.

Authors:  Conor C Lynch; Tracy Vargo-Gogola; Michelle D Martin; Barbara Fingleton; Howard C Crawford; Lynn M Matrisian
Journal:  Cancer Res       Date:  2007-07-15       Impact factor: 12.701

View more
  6 in total

Review 1.  Matrix metalloproteinase inhibitors as investigative tools in the pathogenesis and management of vascular disease.

Authors:  Mina M Benjamin; Raouf A Khalil
Journal:  Exp Suppl       Date:  2012

Review 2.  Matrix Metalloproteinase Inhibitors as Investigational and Therapeutic Tools in Unrestrained Tissue Remodeling and Pathological Disorders.

Authors:  Jie Liu; Raouf A Khalil
Journal:  Prog Mol Biol Transl Sci       Date:  2017-05-10       Impact factor: 3.622

Review 3.  Matrix metalloproteinases as potential targets in the venous dilation associated with varicose veins.

Authors:  Arda Kucukguven; Raouf A Khalil
Journal:  Curr Drug Targets       Date:  2013-03       Impact factor: 3.465

4.  Discovery of a New Class of Potent MMP Inhibitors by Structure-Based Optimization of the Arylsulfonamide Scaffold.

Authors:  Mattia Mori; Assunta Massaro; Vito Calderone; Marco Fragai; Claudio Luchinat; Alessandro Mordini
Journal:  ACS Med Chem Lett       Date:  2013-05-14       Impact factor: 4.345

Review 5.  The Role of Extracellular Proteases in Tumor Progression and the Development of Innovative Metal Ion Chelators that Inhibit their Activity.

Authors:  Kyung Chan Park; Mahendiran Dharmasivam; Des R Richardson
Journal:  Int J Mol Sci       Date:  2020-09-16       Impact factor: 5.923

6.  Role of the Substrate Specificity-Defining Residues of Human SIRT5 in Modulating the Structural Stability and Inhibitory Features of the Enzyme.

Authors:  Junru Yu; Manas Haldar; Sanku Mallik; D K Srivastava
Journal:  PLoS One       Date:  2016-03-29       Impact factor: 3.240

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.